Therapeutic cancer vaccines in the treatment of non-small-cell lung cancer

Expert Review of Vaccines

Volumn 12, Issue 3, 2013, Pages 263-270

  Limacher, Jean Marc ^a   Spring Giusti, Clémentine ^a   Bellon, Nadine ^a   Ancian, Philippe ^a   Rooke, Ronald ^a   Bonnefoy, Jean Yves ^a  

^a TRANSGENE S A   (France)

Author keywords

cancer vaccine; immunotherapy; lung cancer; MUC 1; NSCLC; predictive biomarker

Indexed keywords

ARSENIC TRIOXIDE; BELAGENPUMATUCEL L; BRENTUXIMAB VEDOTIN; BUSULFAN; CANCER VACCINE; CAPECITABINE; CETUXIMAB; CISPLATIN; CRIZOTINIB; DASATINIB; DENILEUKIN DIFTITOX; EMEPEPIMUT S; EP 2101; ERLOTINIB; EXEMESTANE; FULVESTRANT; GEFITINIB; GEMCITABINE; GI 4000; GI 6207; GSK 1572932A; IMATINIB; MELANOMA ANTIGEN 3; TERTOMOTIDE; TG 4010; TIOGUANINE; TOSITUMOMAB; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VEMURAFENIB;

BREAST CANCER; CANCER CELL; CANCER PATIENT; CANCER STAGING; CANCER THERAPY; DRUG DOSE ESCALATION; FOLLOW UP; GENE OVEREXPRESSION; HUMAN; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; INFLUENZA; INJECTION SITE PAIN; LUNG NON SMALL CELL CANCER; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW;

CANCER VACCINES; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNOTHERAPY, ACTIVE; LUNG NEOPLASMS; MEMBRANE GLYCOPROTEINS;

EID: 84875168650     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/erv.13.14     Document Type: Review

References (44)

1. Reck M. Current approaches in chemotherapy of advanced and metastatic non-small cell lung cancer (NSCLC). Anticancer Res. 25(3A), 1501-1506 (2005).
2. Auberger J, Loeffler-Ragg J, Wurzer W, Hilbe W. Targeted therapies in non-small cell lung cancer: proven concepts and unfulfilled promises. Curr. Cancer Drug Targets 6(4), 271-294 (2006).
3. Hirschowitz EA, Yannelli Jr. Immunotherapy for lung cancer. Proc. Am. Thorac. Soc. 6(2), 224-232 (2009).
4. Gérard C, Debruyne C. Immunotherapy in the landscape of new targeted treatments for non-small cell lung cancer. Mol. Oncol. 3(5-6), 409-424 (2009).
5. O'Mahony D, Kummar S, Gutierrez ME. Non-small-cell lung cancer vaccine therapy: a concise review. J. Clin. Oncol. 23(35), 9022-9028 (2005).
6. Acres B, Limacher JM. MUC1 as a target antigen for cancer immunotherapy. Expert Rev. Vaccines 4(4), 493-502 (2005).
7. Hareuveni M, Tsarfaty I, Zaretsky J et al. A transcribed gene, containing a variable number of tandem repeats, codes for a human epithelial tumor antigen. cDNA cloning, expression of the transfected gene and over-expression in breast cancer tissue. Eur. J. Biochem. 189(3), 475-486 (1990).
8. Burchell J, Gendler S, Taylor-Papadimitriou J et al. Development and characterization of breast cancer reactive monoclonal antibodies directed to the core protein of the human milk mucin. Cancer Res. 47(20), 5476-5482 (1987).
9. Kufe DW. Mucins in cancer: function, prognosis and therapy. Nat. Rev. Cancer 9(12), 874-885 (2009).
10. Guddo F, Giatromanolaki A, Koukourakis MI et al. MUC1 (episialin) expression in non-small cell lung cancer is independent of EGFR and c-erbB-2 expression and correlates with poor survival in node positive patients. J. Clin. Pathol. 51(9), 667-671 (1998).
11. Ohgami A, Tsuda T, Osaki T et al. MUC1 mucin mRNA expression in stage I lung adenocarcinoma and its association with early recurrence. Ann. Thorac. Surg. 67(3), 810-814 (1999).
12. Butts C, Maksymiuk A, Goss G et al. Updated survival analysis in patients with stage IIIB or IV non-small-cell lung cancer receiving BLP25 liposome vaccine (L-BLP25): phase IIB randomized, multicenter, open-label trial. J. Cancer Res. Clin. Oncol. 137(9), 1337-1342 (2011).
13. Tyagi P, Mirakhur B. MAGRIT: the largest-ever Phase III lung cancer trial aims to establish a novel tumor-specific approach to therapy. Clin. Lung Cancer 10(5), 371-374 (2009).
14. Barve M, Bender J, Senzer N, et al. Induction of immune responses and clinical efficacy in a phase II trial of IDM-2101, a 10-epitope cytotoxic T-lymphocyte vaccine, in metastatic non-small-cell lung cancer. J. Clin. Oncol. 26(27), 4418-4425 (2008).
15. Brunsvig PF, Kyte JA, Kersten C et al. Telomerase peptide vaccination in NSCLC: a Phase II trial in stage III patients vaccinated after chemoradiotherapy and an 8-year update on a Phase I/II trial. Clin. Cancer Res. 17(21), 6847-6857 (2011).
16. Nemunaitis J, Dillman RO, Schwarzenberger PO et al. Phase II study of belagenpumatucel-L, a transforming growth factor ?-2 antisense gene-modified allogeneic tumor cell vaccine in non-small-cell lung cancer. J. Clin. Oncol. 24(29), 4721-4730 (2006).
17. Nemunaitis J, Nemunaitis M, Senzer N et al. Phase II trial of Belagenpumatucel- L, a TGF-2 antisense gene modified allogeneic tumor vaccine in advanced non small cell lung cancer (NSCLC) patients. Cancer Gene Ther. 16(8), 620-624 (2009).
18. Cohen S, Kaufman HL. TG-4010 Transgene. Curr. Opin. Investig. Drugs 5(12), 1319-1328 (2004).
19. Rochlitz C, Figlin R, Squiban P et al. Phase I immunotherapy with a modified vaccinia virus (MVA) expressing human MUC1 as antigen-specific immunotherapy in patients with MUC1-positive advanced cancer. J. Gene Med. 5(8), 690-699 (2003).
20. Ramlau R, Quoix E, Rolski J et al. A Phase II study of TG4010 (MVA?MUC1-Il2) in association with chemotherapy in patients with stage III/IV non-small cell lung cancer. J. Thorac. Oncol. 3(7), 735-744 (2008).
21. Quoix E, Ramlau R, Westeel V, et al. Therapeutic vaccination with TG4010 and first-line chemotherapy in advanced non-small-cell lung cancer: a controlled Phase 2B trial. Lancet Oncol. 12(12), 1125-1133 (2011).
22. Wang Y, Rouggly L, You M, Lubet R. Animal models of lung cancer characterization and use for chemoprevention research. Prog. Mol. Biol. Transl. Sci. 105, 211-226 (2012).
23. Acres B, Apostolopoulos V, Balloul JM et al. MUC1-specific immune responses in human MUC1 transgenic mice immunized with various human MUC1 vaccines. Cancer Immunol. Immunother. 48(10), 588-594 (2000).
24. Berndt A, Cario CL, Silva KA et al. Identification of fat4 and tsc22d1 as novel candidate genes for spontaneous pulmonary adenomas. Cancer Res. 71(17), 5779-5791 (2011).
25. Wang D, You M. Five loci, SLT1 to SLT5, controlling the susceptibility to spontaneously occurring lung cancer in mice. Cancer Res. 65(18), 8158-8165 (2005).
26. Kreisel D, Gelman AE, Higashikubo R et al. Strain-specific variation in murine natural killer gene complex contributes to differences in immunosurveillance for urethane-induced lung cancer. Cancer Res. 72(17), 4311-4317 (2012).
27. Tanaka-Okamoto M, Hori K, Ishizaki H et al. Increased susceptibility to spontaneous lung cancer in mice lacking LIMdomain only 7. Cancer Sci. 100(4), 608-616 (2009).
28. Meuwissen R, Berns A. Mouse models for human lung cancer. Genes Dev. 19(6), 643-664 (2005).
29. DuPage M, Mazumdar C, Schmidt LM, Cheung AF, Jacks T. Expression of tumour-specific antigens underlies cancer immunoediting. Nature 482(7385), 405-409 (2012).
30. Turner MS, Cohen PA, Finn OJ. Lack of effective MUC1 tumor antigen-specific immunity in MUC1-transgenic mice results from a Th/T regulatory cell imbalance that can be corrected by adoptive transfer of wild-type Th cells. J. Immunol. 178(5), 2787-2793 (2007).
31. Chakraborty M, Schlom J, Hodge JW. The combined activation of positive costimulatory signals with modulation of a negative costimulatory signal for the enhancement of vaccine-mediated T-cell responses. Cancer Immunol. Immunother. 56(9), 1471-1484 (2007).
32. Mulryan K, Ryan MG, Myers KA et al. Attenuated recombinant vaccinia virus expressing oncofetal antigen (tumor-associated antigen) 5T4 induces active therapy of established tumors. Mol. Cancer Ther. 1(12), 1129-1137 (2002).
33. Harrop R, Connolly N, Redchenko I et al. Vaccination of colorectal cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax) induces immune responses which correlate with disease control: a Phase I/II trial. Clin. Cancer Res. 12(11 Pt 1), 3416-3424 (2006).
34. Ryan SO, Turner MS, Gariépy J, Finn OJ. Tumor antigen epitopes interpreted by the immune system as self or abnormal-self differentially affect cancer vaccine responses. Cancer Res. 70(14), 5788-5796 (2010).
35. Kwak EL, Bang YJ, Camidge DR et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N. Engl. J. Med. 363(18), 1693-1703 (2010).
36. Bergethon K, Shaw AT, Ou SH et al. ROS1 rearrangements define a unique molecular class of lung cancers. J. Clin. Oncol. 30(8), 863-870 (2012).
37. Brichard VG, Lejeune D. GSK's antigenspecific cancer immunotherapy programme: pilot results leading to Phase III clinical development. Vaccine 25(Suppl. 2), B61-B71 (2007).
38. Vetsika EK, Konsolakis G, Aggouraki D et al. Immunological responses in cancer patients after vaccination with the therapeutic telomerase-specific vaccine Vx-001. Cancer Immunol. Immunother. 61(2), 157-168 (2012).
39. Lu Y, Bellgrau D, Dwyer-Nield LD et al. Mutation-selective tumor remission with Ras-targeted, whole yeast-based immunotherapy. Cancer Res. 64(15), 5084-5088 (2004).
40. Acres B, Marie-Bastien B, Grellier B, et al. A signature of circulating biomarkers correlates with clinical outcome in a randomized phase IIb trial evaluating the therapeutic vaccine TG4010 in NSCLC patients. Proc. Am. Assoc. Cancer Res. Denver CO. AACR Abstract 733, 718-722 (2009).
41. Merck Serono press release. www.merckserono.com/corp.merckserono- 2011/en/images/Stimuvax%20 START-20121219-FINAL-1- tcm1494-104186.pdf?Version=
42. National Cancer Institute, Cancer Models database. http://cancermodels. nci.nih.gov/camod/ searchResults.do
43. Center for Biologics Evaluation and Research (CBER). Guidance for Industry: Clinical Considerations for Therapeutic Cancer Vaccines. www.fda.gov/downloads/BiologicsBlood- Vaccines/GuidanceComplianceRegulatory- Information/Guidances/Vaccines/ UCM182826.pdf
44. ClinicalTrials.gov. http://clinicaltrials.gov